Advertisement
Canada markets open in 2 hours 14 minutes

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7314
    +0.0016 (+0.22%)
     

  • CRUDE OIL

    82.89
    +0.08 (+0.10%)
     

  • Bitcoin CAD

    87,028.79
    -3,799.51 (-4.18%)
     

  • CMC Crypto 200

    1,349.11
    -33.46 (-2.42%)
     

  • GOLD FUTURES

    2,340.50
    +2.10 (+0.09%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,483.25
    -181.25 (-1.03%)
     

  • VOLATILITY

    16.26
    +0.29 (+1.82%)
     

  • FTSE

    8,086.55
    +46.17 (+0.57%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6817
    -0.0002 (-0.03%)
     

Today's Research Reports on Trending Tickers: Aurora Cannabis and Tilray

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / December 13, 2018 / While some marijuana stocks were getting a boost in share price as Wall Street learned that the U.S. Senate passed the farm bill, Tilray Inc. wasn't one of them. Shares of Tilray sank over 10% yesterday. Aurora Cannabis managed to close up in the green though.

The Market Edge Initiates Coverage on:

Aurora Cannabis Inc.
https://marketedgereport.com/report/ACB/

Tilray, Inc.
https://marketedgereport.com/report/TLRY/

Aurora Cannabis Inc. shares closed up 3.20% on roughly 13.4 million shares traded yesterday. There was no immediate news yesterday but recently Aurora announced a supply deal with Mexico’s Farmacias Magistrales SA. The company entered a letter of intent to buy all of the company’s outstanding shares in an all-stock deal. The deal “firmly establishes Aurora’s first-mover advantage in one of the world’s most populous countries, where more than 130 million people will have federally legal access to a range of Aurora’s non-flower medical cannabis products containing THC,” said a statement. “Integrating Farmacias with our operations in Canada and Latin America will not only accelerate growth, it will build substantial long-term shareholder value,” Aurora Chief Executive Terry Booth remarked.

ADVERTISEMENT

Access The Market Edge's Aurora Cannabis Inc. Research Report:
https://marketedgereport.com/report/ACB/

Tilray, Inc. shares were down 10.19% on Wednesday with almost 2.4 million shares traded. There was no news from the company to explain the sell off. It was last month that the Canadian pharmaceutical and cannabis company reported earnings. For the third quarter, Tilray reported a loss of 8 cents, better than the loss of 12 cents that analysts had expected. Revenue at $10.05 million was in line with estimates. "All of that revenue for this quarter is medical and we look forward to next quarter, when we’ll start to see some Canadian adult-use revenue in that earnings report," said CEO Brendan Kennedy. He added, "The biggest challenge is that there’s just so much demand, which is interesting to see,” he added. “It definitely takes six to 12 months for supply and demand to reach some sort of equilibrium."

Access The Market Edge's Tilray, Inc. Research Report:
https://marketedgereport.com/report/TLRY/

Our Actionable Research on Aurora Cannabis Inc. (NYSE: ACB) and Tilray, Inc. (NASDAQ: TLRY) can be downloaded free of charge at The Market Edge.

The Market Edge

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

The Market Edge has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of MarketEdgeReport.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. MarketEdgeReport.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.marketedgereport.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

The Market Edge, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@marketedgereport.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: The Market Edge